Market Research Logo

Dendrimers and Polymer Drug Conjugates Market, 2016 - 2026

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. The Concept of Nanotechnology
3.2. Nanomedicine: A Potential Platform for Therapeutic Applications
3.3. Applications of Nanomedicine
3.3.1. Drug Delivery
3.3.2. Diagnostic Techniques
3.3.3. Anti-Microbial Techniques
3.3.4. Therapeutic Techniques
3.3.5. Surgery
3.3.6. Gene Therapy
3.3.7. Imaging
3.4. Nanocarriers: Important Tools for Nanomedicine
3.4.1. Nanoparticles
3.4.2. Carbon Nanotubes (CNTs)
3.4.3. Polymer Conjugates
3.4.4. Nanocrystals
3.4.5. Dendrimers
3.5. Nanocarriers and Drug Approvals
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Dendrimers: Product List and Classes
4.3. Polymer Drug Conjugates: Development Pipeline
4.3.1. Distribution by Phase of Development
4.3.2. Distribution by Type of Disease Area
4.3.3. Distribution by Type of Polymer
4.3.4. Distribution by Type of Drug
4.3.5. Leading Players of the Industry
5. DENDRIMERS: A DETAILED REVIEW
5.1. An Introduction to Dendrimers
5.2. Synthesis of Dendrimers
5.2.1. Divergent Mode of Synthesis
5.2.2. Convergent Mode of Synthesis
5.3. Characterization of Dendrimers
5.3.1. Spectroscopic Techniques
5.3.2. Microscopy
5.3.3. Size Exclusion Chromatography
5.3.4. Other Techniques
5.4. Properties of Dendrimers
5.5. Advantages of Dendrimers
5.6. Applications of Dendrimers
5.6.1. Drug Delivery
5.6.2. Mimics of Globular Proteins
5.6.3. Gene Transfection
5.6.4. Imaging and Diagnostics
5.6.5. Solubility Enhancers
5.6.6. Modification of Electrodes
5.6.7. Development of Vaccines
5.7. Classification of Dendrimers
5.8. Types of Dendrimers
5.9 Commercialized Dendrimers
5.9.1. PAMAM/Starburst®
5.9.1.1. Specifications
5.9.1.2. Structure and Synthesis
5.9.1.3. Properties
5.9.1.4. Products Based on PAMAM
5.9.1.5. PAMAM: Application in Biopharmaceuticals
5.9.2. Poly-L-Lysine (PLL) Dendrimers (Multiple Antigen Peptide Dendrimers)
5.9.2.1. Specifications
5.9.2.2. Structure
5.9.2.3. Products Based on PLL Dendrimers
5.9.3. Priostar® Dendrimers (Frechet Type Dendrimers)
5.9.3.1. Specifications
5.9.3.2. Priostar®: Applications
5.9.3.3. Products Based on Priostar® Dendrimers
5.9.4. Astramol® (Polypropylenimine (PPI) Dendrimer)
5.9.4.1. Specifications
6. POLYMER DRUG CONJUGATES: DRUG PROFILES
6.1. The Rationale of Polymer Drug Conjugates
6.2. Designing and Characterization of Polymer Drug Conjugates
6.3. Most Common Polymers
6.4. Most Common Drugs
6.5. Advantages of Polymer Drug Conjugates
6.6. Polymer Drug Conjugates in Oncology and Other Diseases
6.7. Polymer Drug Conjugates: Drug Profiles
6.7.1. Nektar Therapeutics
6.7.1.1. Company Overview
6.7.1.2. Product Profile: NKTR-102 / Etirinotecan Pegol
6.7.1.3. Product Profile: NKTR-181
6.7.2. CTI BioPharma
6.7.2.1. Company Overview
6.7.2.2. Product Profile: Opaxio™
6.7.3. Cerulean Pharma
6.7.3.1. Company Overview
6.7.3.2. Product Profile: CRLX101
7. MARKET FORECAST AND OPPORTUNITY ANALYSIS
7.1. Chapter Overview
7.2. Polymer Drug Conjugates: Future Projections
7.2.1. Scope and Limitations
7.2.2. Forecast Methodology
7.2.3. Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
7.2.3.1. NKTR-118 (Nektar Therapeutics)
7.2.3.2. NKTR-102 (Nektar Therapeutics)
7.2.3.3. CRLX101 (Cerulean Pharma)
7.2.3.4. Opaxio™ (CTI BioPharma)
7.3. Dendrimers: Opportunity Areas
7.3.1. Drug Delivery Systems
7.3.2. Research Applications
7.3.3. Therapeutic Applications
7.3.4. Diagnostic Applications
8. CONCLUSION
8.1. The Evolving Era of Polymer Therapeutics Offers Significant Promise to the Pharmaceuticals Market
8.2. Amongst all the Applications, Drug Delivery Holds a Large Opportunity
8.3. The Dendrimer Market is Yet to Unveil its Potential in the Biomedical Industry
8.4. Polymer Drug Conjugates are Being Exploited for Numerous Therapeutic Areas
8.5. With Success of the Already Commercialized Drugs, the Next Generation of Polymer Drug Conjugates are Poised to Witness an Accelerated Growth
9. APPENDIX 1: TABULATED DATA
10. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Application of Nanomedicines
Figure 3.2 Nanomedicine Drug Delivery: Applications in Key Therapeutic Areas
Figure 3.3 Challenges Associated with Drug Delivery in Nanotechnology
Figure 3.4 Classification of Nanocarriers
Figure 3.5 Properties of Carbon Nanotubes
Figure 3.6 Properties of Dendrimers
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Disease Area
Figure 4.3 Pipeline Analysis: Distribution by Type of Polymer
Figure 4.4 Pipeline Analysis: Distribution by Type of Drug
Figure 4.5 Polymer Drug Conjugates: Key Players
Figure 5.1 Dendrimers: Advantages
Figure 5.2 Dendrimer versus Linear Polymers
Figure 5.3 Dendrimers: Classification
Figure 5.4 Dendrimers: Types
Figure 5.5 SuperFect® Transfection Reagent: Applications
Figure 5.6 SuperFect® Transfection Reagent: Protocol
Figure 5.7 Polyfect® Transfection Reagent: Protocol
Figure 5.8 PrioFect™: Clinical and Non-Clinical Applications
Figure 5.9 NanoJuice® Transfection Kit: Advantages
Figure 6.1 Polymer Drug Conjugates: Ringsdorf Model
Figure 6.2 Polymer Drug Conjugates: Advantages
Figure 6.3 Application of Polymer Drug Conjugates in Several Indications
Figure 6.4 Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
Figure 6.5 PEGylated Irinotecan: NKTR-102
Figure 6.6 NKTR-102: Mechanism of Action
Figure 6.7 Advantages of NKTR-102 over Irinotecan
Figure 7.1 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
Figure 7.2 Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
Figure 7.3 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.4 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.5 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.6 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.7 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.8 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.9 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.10 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.11 Collaboration Based Revenues: Illustrative Future Projections
Figure 8.1 Polymer Therapeutics versus Conventional Therapeutics
Figure 8.2 Polymer Drug Conjugates: Emerging Therapeutic Areas
Figure 8.3 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026 
LIST OF TABLES
Table 3.1 Approved Nanocrystal Drugs
Table 3.2 List of Commercialized Nanomedicines
Table 4.1 Dendrimers: Product List and Classes
Table 4.2 Polymer Drug Conjugates: Development Pipeline
Table 5.1 List of Drugs Loaded in Dendrimers
Table 5.2 List of Commercialized Dendrimers
Table 5.3 Dendritech: List of PAMAM Dendrimers
Table 5.4 Stratus® CS: Type of Biomarkers
Table 5.5 SuperFect™ Transfection Reagent: Product Details
Table 5.6 PolyFect® Transfection Reagent: Product Details
Table 5.7 PolyFect® Transfection Reagent: Product Details
Table 5.8 PAMAM: Biotherapeutic Applications
Table 5.9 VivaGel®: Current Status of Development
Table 5.10 VivaGel®: Current Status of Development
Table 5.11 VivaGel®: Clinical Trial Endpoints
Table 5.12 Gadomer-17: Product Specifications
Table 5.13 PPI Dendrimers: Price and Quantity
Table 6.1 Approved Polymer Drug Conjugates
Table 6.2 Polymer Drug Conjugates: Profiled Drugs
Table 6.3 NKTR-102: Current Status of Development
Table 6.4 NKTR-102: Clinical Trials
Table 6.5 NKTR-102: Phase II Clinical Trial Endpoints (Breast Cancer, Ovarian Cancer, Colorectal Cancer, Lung Cancer)
Table 6.6 NKTR-102: Phase II Clinical Trial Endpoints (Glioma, Solid Tumors)
Table 6.7 NKTR-102 versus TPC: Adverse Events
Table 6.8 NKTR-181: Current Status of Development
Table 6.9 NKTR-181: Clinical Trials
Table 6.10 NKTR-181: Clinical Trials
Table 6.11 Opaxio™: Current Status of Development
Table 6.12 Opaxio™: Clinical Studies
Table 6.13 Opaxio™: Clinical Trial Endpoints for Ovarian Epithelial, Peritoneal and Fallopian Tube Cancer
Table 6.14 Opaxio™: Clinical Trial Endpoints for Other Indications
Table 6.15 CRLX101: Current Status of Development
Table 6.16 CRLX101: Clinical Studies
Table 6.17 CRLX101: Clinical Trial Endpoints (Phase II Studies)
Table 6.18 CRLX101: Clinical Trial Endpoints (Phase I/II Studies)
Table 7.1 Polymer Drug Conjugates: Market Potential of Candidates
Table 7.2 NKTR-181: Target Patient Population
Table 7.3 NKTR-102: Target Patient Population
Table 7.4 CRLX101: Target Patient Population
Table 7.5 Opaxio™: Target Patient Population
Table 7.6 Dendrimers: Opportunity Areas
Table 7.7 Drug Delivery Systems: Example List
Table 7.8 Commercialized Dendrimer-Based Kits
Table 9.1 Pipeline Analysis: Distribution by Phase of Development
Table 9.2 Pipeline Analysis: Distribution by Type of Disease Area
Table 9.3 Pipeline Analysis: Distribution by Type of Polymer
Table 9.4 Pipeline Analysis: Distribution by Type of Drug
Table 9.5 Polymer Drug Conjugates: Key Players
Table 9.6 Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
Table 9.7 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
Table 9.8 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Optimistic Scenario)
Table 9.9 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Conservative Scenario)
Table 9.10 Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
Table 9.11 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.12 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.13 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.14 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.15 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.16 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.17 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.18 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.19 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.20 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.21 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.22 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.23 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.24 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.25 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.26 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.27 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.28 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.29 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.30 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.31 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.32 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.33 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.34 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.35 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026

Dendrimers and Polymer Drug Conjugates Market, 2016 - 2026

As defined by the National Nanotechnology Initiative, nanotechnology is the branch of science that deals with materials smaller than 100 nanometers. Nanomedicines are nanosized particles that help in the diagnosis, treatment and monitoring of therapeutic agents. The discovery of several nanocarriers such as polymers, proteins, micelles, dendrimers, liposomes, emulsions, nanoparticles, each with a unique structure, has provided the drug developers with options to improve the pharmacokinetics and release properties of their existing drugs.

Within the biomedical sector, nanocarriers have an array of therapeutic and diagnostic applications. These include drug delivery, targeted therapy, gene therapy, development of diagnostic assays, molecular imaging and a number of research applications. Specifically, drug delivery has emerged as one of the most popular applications that enhances the therapeutic efficacy of biomolecules. Several competing drug delivery approaches are being explored for their efficacy with various routes of administration.

Dendrimers, owing to their structural flexibility, hold potential for several medical and non-medical applications; however, their use in the biomedical field is yet to be fully explored. Several academic institutes and organizations are conducting intense research to explore the therapeutic and diagnostic potential of dendrimers. With a number of commercial dendrimers-based products (both biomedical and agro-based), Starpharma is a prominent player in this domain.

On the other hand, polymer drug conjugates is a well-established segment with several commercialized products. The current polymer drug conjugates market has over 10 approved drug candidates for a wide range of molecular targets and disease areas. Examples include (in alphabetical order) Adynovate by Baxalta, Doxil® by Pfizer/ Sun Pharmaceuticals, Krystexxa® by Savient Pharmaceuticals / Crealta Pharmaceuticals, Movantik™ by AstraZeneca, Oncospar® by Enzon Pharmaceuticals, Plegridy® by Biogen. Despite an already well-established market, the field has gathered interest of several other players to explore the complete potential of polymer drug conjugates in different therapeutic areas. The clinical outcomes and the success of the current clinical molecules will decide the fate of the future market.

SCOPE OF THE REPORT
The “Dendrimers and Polymer Drug Conjugates Market, 2016-2026” report delivers a comprehensive study on the emergence of nanocarriers as a significant tool for drug delivery, therapeutics and diagnostics. For the purpose of this report, we have primarily focused on the following two types of nanocarriers.
 Dendrimers
 Polymer drug conjugates

Dendrimers, the nanoscale hyper-branched structures, are evolving in the healthcare sector to enhance the properties of existing therapeutic compounds as well as for introduction of novel therapeutic/diagnostic products. VivaGel® by Starpharma is a commercially available therapeutic product; in addition, transfection kits and diagnostic assays are also available. However, from a commercial perspective, market of dendrimers is still in its infancy within the biomedical sector. The domain is gradually gaining traction with several technologies and approaches being designed for improving drug release properties. In addition to drug delivery, which is the key application area, some other potential applications of dendrimers being actively pursued in research include disease diagnosis, targeted therapy, MRI imaging, tissue regeneration, cell repair and vaccine development.

A parallel field of polymer therapeutics includes introduction of polymers with conventional drugs; these are more commonly known as polymer drug conjugates. Conjugation of drugs with polymers has demonstrated a marked improvement in their efficacy and release profiles. For the purpose of our study, we have included the molecules in the clinical/preclinical development (defined as per the Ringsdorf Model). Numerous polymer drug conjugates have already been commercialized for a wide range of therapeutic areas; our study provides an analysis of key disease areas being targeted by the developers of polymer drug conjugates. Several well-known anti-cancer drugs such as docetaxel, paclitaxel and doxorubicin have been conjugated with polymers such as PEG, HPMA and PLA to enhance their water solubility, half-life, efficacy and body clearance.

The report assesses key drivers that have governed the evolution of polymer drug conjugates over the past several years and determines the market in a long term (2016-2026). The research, analysis and insights presented in this report include potential sales of the drugs in phase III and phase II of development. To add robustness to our forecast model, we have provided three market scenarios. The conservative, base and optimistic scenarios represent three different tracks of market evolution. In addition, we have provided a detailed discussion on the future trends and the key opportunity areas for dendrimers that are likely to shape the market in the coming years.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. Nearly 40 polymer drug conjugates are currently in clinical and preclinical stages of development; molecules in phase III and II account for nearly 19% of the pipeline while 26% is captured by molecules in phase I/II and I.
2. There are several types of dendrimers being used for both commercial and research purposes in the pharmaceutical domain; the dendrimers most widely used for industry applications include PAMAM, PLL, Priostar®, Astramol®. However, with over 4000 papers published between 2006 and 2016 (as reported in PubMed), dendrimers are being extensively explored by researchers in the non-industry / academic institutes.
3. With one commercialized therapeutic product (VivaGel®) and several other marketed dendrimer-based products (SuperFect®, Stratus® CS, PrioFect™, Alert Ticket™), Starpharma has emerged as a forerunner in the dendrimer market.
4. Amongst the different biomedical applications that dendrimers and polymer drug conjugates serve, drug delivery holds a large opportunity. Several big pharma players as AstraZeneca, Eli Lilly, GSK’s Stiefel have collaborated with dendrimer technology developers (such as DEP® Technology by Starpharma) to improve the therapeutic efficacy and drug delivery properties of their existing products. Additionally, polymer drug conjugates have expanded their focus to a broad range of diseases exploring different routes of administrations for better drug delivery.
5. The polymer drug conjugates market momentum will be driven by the success of current batch of late stage clinical molecules; these primarily include NKTR-181 (by Nektar Therapeutics), NKTR-102 (by Nektar Therapeutics), CRLX-101 (by Cerulean Pharma) and Opaxio™ (by CTI BioPharma).
6. Specific molecules such as NKTR-181 and NKTR-102 are anticipated to achieve a blockbuster status in the near future. With eight molecules (two mentioned above and six others in lower stages of development) in development, Nektar Therapeutics is expected to play an important role in the market’s evolution.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the report. It offers a high level view on the present scenario of dendrimers and polymer drug conjugates and where they are headed in the mid to long term.

Chapter 3 provides a general introduction to nanotechnology with a detailed discussion on its applications in the biopharmaceutical industry. This chapter discusses the various types of nanocarriers that have revolutionized drug delivery and other biomedical applications.
Chapter 4 includes information on nearly 40 polymer drug conjugates that are being evaluated in different stages of development (both clinical and preclinical/discovery). In this chapter, we have identified the companies that are active in this market and conducted a detailed pipeline analysis including information on type of polymers, type of drugs, most commonly targeted indications and the phase of development. In addition, we have provided a list of the different classes of dendrimers highlighting their developer, core molecules and surface groups.

Chapter 5 provides an in-depth introduction to dendrimers. In this chapter, we have captured the most popular dendrimers used for development of diagnostics, therapeutics and other biomedical products; these are accompanied with detailed information on their structure, research applications and detailed product profiles of the commercialized products.

Chapter 6 comprises of a comprehensive discussion on the advantages, applications and target disease areas of polymer drug conjugates. In addition, the chapter gives detailed profiles of phase III and phase II molecules including information of their developer, clinical trials and primary/secondary endpoints.

Chapter 7 offers a comprehensive view on the market forecast of polymer drug conjugates measuring the opportunity in the next ten years. Due to the uncertainty surrounding some of the key assumptions, we have presented three different evolution scenarios for the overall market. In addition, we have presented a qualitative analysis of the opportunity areas of dendrimers highlighting their future potential.

Chapter 8 summarizes the overall report. In this chapter, we have provided a recap of the key takeaways and our overall opinion on where the market is headed in the mid-long term.

Chapter 9 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 10 is an appendix, which provides a list of companies and organizations mentioned in the report. 

LIST OF COMPANIES AND ORGANIZATIONS

1. 3S Bio
2. Abeona Therapeutics
3. Abramson Cancer Center
4. Access Pharmaceuticals
5. Adama
6. Ajinomoto Althea
7. Allergan
8. Alliance for Clinical Trials in Oncology
9. Allied Corporation
10. Althea Technologies
11. Altus Pharmaceuticals
12. Amgen
13. Ansell Limited
14. Arsenal Medical
15. ASCEND Therapeutics
16. Ascendis Pharma
17. Aspen Pharmacare
18. AstraZeneca
19. Baxalta
20. Belrose Pharma
21. Beth Israel Deaconess Medical Center
22. BIND Sciences
23. Biogen
24. Brown University
25. Cancer Therapeutics
26. Carlina Technologies
27. Cellular Therapeutics
28. Cerulean Pharma
29. City of Hope Medical Center
30. Clemson University
31. Colcom
32. Cosmo Pharmaceuticals
33. Crealta Pharmaceuticals
34. CTI BioPharma
35. CytImmune
36. Dade Behring
37. Dana-Farber Cancer Institute
38. Dartmouth-Hitchcock Medical Center
39. DelSiTech
40. Delta-Fly Pharma
41. Dendritech Nanotechnologies
42. Dow Chemical
43. Durect Corporation
44. Edge Therapeutics
45. Eli Lilly
46. EMD Biosciences
47. Enzon Pharmaceuticals
48. Eunice Kennedy Shriver National Institute of Child Health and Human Development
49. Eyetech
50. Ferring
51. Flamel Technologies
52. Genentech
53. GlaxoSmithKline
54. Gowan
55. Gynecologic Oncology Group Foundation
56. JenKem Technology
57. Landec
58. Lipotek
59. M.D. Anderson Cancer Center
60. Makhteshim Agan
61. Massachusetts General Hospital
62. Massachusetts Institute of Technology
63. Memorial Sloan Kettering Cancer Center
64. Merck
65. Mersana Therapeutics
66. Michigan Nanotechnology Institute for Medicine and Biological Sciences
67. Mountain View Pharmaceuticals
68. Mylan
69. Nanovector
70. National Cancer Institute
71. National Heart and Lung Institute
72. National Institute of Allergy and Infectious Diseases
73. National Institutes of Health
74. National Institute of Mental Health
75. National Institute on Drug Abuse
76. National Nanotechnology Initiative
77. Nektar Therapeutics
78. NeuroNano Pharma
79. Novartis
80. Nufarm
81. Oakwood Laboratories
82. Octoplus
83. Okamoto Industries
84. Ontario Institute for Cancer Research
85. Peptineo
86. Pfizer
87. PG-TXL
88. Pharmacia and Upjohn Company
89. PolyActiva
90. Polymer Factory
91. PolyPid
92. ProCore Bio Med
93. ProLynx
94. pSivida
95. Qiagen
96. Reckitt Benckiser
97. Rexahn Pharmaceuticals
98. Roche
99. Roswell Park Cancer Institute
100. Sagent Pharmaceuticals
101. Sanofi-Aventis
102. Santarus
103. Savient Pharmaceuticals
104. Schering Plough
105. Serina Therapeutics
106. Shire
107. Sigma Aldrich
108. Sitka Biopharma
109. Sloan-Kettering Institute for Cancer Research
110. Sonoran Biosciences
111. Stanford Cancer Institute
112. Stanford University
113. Starpharma
114. Stiefel Laboratories
115. Sun Pharma
116. SUNY Upstate Medical University
117. SyMO-Chem
118. Teva Pharmaceutical
119. The Methodist Hospital System
120. The State University of New York
121. UCB Pharma
122. UNC Lineberger Comprehensive Cancer Center
123. University of Chicago
124. University of Colorado Boulder
125. University of Glasgow
126. University of Illinois
127. University of Maryland
128. University of Pennsylvania
129. University of Southern California
130. University of Washington
131. US Army Research Laboratory
132. Weihai CY
133. World Health Organization
134. Wyss Institute
135. XstalBio
136. Yamanouchi


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;